Business Wire

UNIONPAY

29.7.2020 10:02:43 CEST | Business Wire | Press release

Share
UnionPay Announces Partnership With Fast Growing Digital Platform Glovo

UnionPay International, the card payment organisation with the world’s largest cardholder base, today announces a partnership with Glovo, the Barcelona-based on-demand economy technology start-up, which enables UnionPay cardholders to use its app initially in Spain, Portugal, France and Italy.

Founded in 2015, Glovo is an on-demand economy technology start-up that allows local stores to offer their products in the same city through the GLOVO App and supports intermediates in the delivery of such products. It is currently present in 22 countries including Croatia, France, Georgia, Italy, Poland, Portugal, Romania, Serbia, Spain and Ukraine.

This new partnership with Glovo enables UnionPay cardholders to make a wider range of purchases without the need to leave home. To encourage take up of the service while some lockdown measures are still in place, UnionPay customers have been offered free delivery until 15 August in Spain, Portugal and France.

UnionPay acceptance in France, Italy, Portugal and Spain has grown significantly in the last 12 months with a large number of online and offline merchants now accepting UnionPay cards. UnionPay’s cardholder base comprises Chinese ex-pats living and working in Europe, students from Asian countries, as well as a rapidly increasing domestic customer base among European nationals. This is particularly the case in Portugal where last year Millennium bcp became the first European bank to issue UnionPay cards.

Wei Zhihong, UnionPay International’s Market Director and Head of Europe said : “As one of the largest bankcard schemes worldwide, we are committed to providing payment ease for our cardholders. In this difficult time, we are making an extra effort, together with our partners, to offer safer and easier services to support our cardholders in Europe. We are very pleased to have reached a partnership with one of the world’s leading on-demand economy technology start-ups. Glovo is a company which has grown rapidly since its foundation in 2015 and through this new partnership the reach of its app is extended to our cardholders.

“With consumer behaviour changing as a result of COVID-19, more people are staying indoors and making purchases. This new partnership will enable our customers to benefit from Glovo’s platform and service, making purchases and arranging pick-ups without having to leave their own home. We are happy that we have been able to agree a delivery fee free period with Glovo to help keep costs down for cardholders. We look forward to announcing many more similar partnerships in the very near future.”

Sacha Michaud, Co-founder of Glovo said: “We are delighted to have reached a new partnership with UnionPay and hope that it represents the beginning of a long-term relationship which will benefit UnionPay card holders throughout France, Italy, Portugal and Spain. We look forward to working together on further partnerships as we move forward.”

With over 8.4 billion cards accumulatively issued worldwide, UnionPay is the card payment organisation with the world’s largest cardholder base. Its global network extends to 179 countries and regions, covering over 52 million merchants and more than 2.9 million ATMs worldwide.

- Ends -

About UnionPay International

UnionPay International (UPI) is a subsidiary of China UnionPay focused on the growth and support of UnionPay’s global business. In partnership with more than 2300 institutions worldwide, UnionPay

International has enabled card acceptance in 179 countries and regions with issuance in 61 countries and regions. UnionPay International provides high quality, cost effective and secure cross-border payment services to the world’s largest cardholder base and ensures convenient local services to a growing number of global UnionPay cardholders and merchants.

For more information, please visit: www.unionpayintl.com/en

For media enquiries please contact:

Citigate Dewe Rogerson

Oliver Parry/ Brandon Stockwell/ Patrick Evans

unionpay@citigatedewerogerson.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)21.9.2026 07:03:00 CEST | Press release

Curatis Holding AG (SIX:CURN, “Curatis”) reports net sales from goods and services of CHF 7.9m for the first half of 2026, up 51% (H1 2025: CHF 5.2m), with the loss for the period narrowing to CHF -0.4m (H1 2025: CHF -1.2m) and cash and cash equivalents rising to CHF 3.6m (31 December 2025: CHF 1.9m). Curatis also advanced its corticorelin (C-PTBE-01) program on multiple levels, including an exclusive Japan licence with Neupharma and continued manufacturing progress. Business development and finances Net sales from goods increased by 46% to CHF 7.4m (H1 2025: CHF 5.0m) and net sales from services rose to CHF 0.6m (H1 2025: CHF 0.2m). Growth was driven both by products marketed for some time and by products added to the distribution portfolio in 2025 and 2026. The gross contribution from goods and services rose by 32% to CHF 1.8m (H1 2025: CHF 1.3m); the combined cost base grew by only 9% against net sales growth of 51%, as personnel expenses rose 5% to CHF 1.3m (H1 2025: CHF 1.2m) and

Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies21.9.2026 07:00:00 CEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland's leading blue chip equity benchmark comprising 20 of the country's largest and most liquid listed companies. Less than three years after its IPO on the SIX Swiss Exchange in March 2024, Galderma has established itself as one of Switzerland's leading listed companies. Its inclusion in the SMI reflects the company's strong growth, disciplined execution and increasing relevance in Swiss and international capital markets as it advances its ambition to become the world's leading dermatology powerhouse. Since its IPO, Galderma has continued to execute its growth-focused integrated dermatology strategy, delivering strong performance across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Net sales increased from 4.410 billion USD in 2024 to 5.207 billion USD in 2025, driven by science-led innovation, portfolio and geogr

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye